- Home
- ACRS vs IGA Comparison
ACRS vs IGA Comparison
Compare ACRS & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- IGA
- Stock Information
- Founded
- ACRS 2012
- IGA 2005
- Country
- ACRS United States
- IGA United States
- Employees
- ACRS N/A
- IGA N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- IGA Investment Managers
- Sector
- ACRS Health Care
- IGA Finance
- Exchange
- ACRS Nasdaq
- IGA Nasdaq
- Market Cap
- ACRS 132.0M
- IGA 147.6M
- IPO Year
- ACRS 2015
- IGA N/A
- Fundamental
- Price
- ACRS $2.60
- IGA $9.56
- Analyst Decision
- ACRS Strong Buy
- IGA
- Analyst Count
- ACRS 5
- IGA 0
- Target Price
- ACRS $11.00
- IGA N/A
- AVG Volume (30 Days)
- ACRS 956.3K
- IGA 42.3K
- Earning Date
- ACRS 02-25-2025
- IGA 01-01-0001
- Dividend Yield
- ACRS N/A
- IGA 8.93%
- EPS Growth
- ACRS N/A
- IGA N/A
- EPS
- ACRS N/A
- IGA N/A
- Revenue
- ACRS $27,079,000.00
- IGA N/A
- Revenue This Year
- ACRS N/A
- IGA N/A
- Revenue Next Year
- ACRS N/A
- IGA N/A
- P/E Ratio
- ACRS N/A
- IGA N/A
- Revenue Growth
- ACRS 26.35
- IGA N/A
- 52 Week Low
- ACRS $0.95
- IGA $7.77
- 52 Week High
- ACRS $5.17
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- ACRS 44.33
- IGA 60.14
- Support Level
- ACRS $2.31
- IGA $9.11
- Resistance Level
- ACRS $2.64
- IGA $9.57
- Average True Range (ATR)
- ACRS 0.16
- IGA 0.13
- MACD
- ACRS 0.02
- IGA 0.04
- Stochastic Oscillator
- ACRS 58.76
- IGA 89.13
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.